Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. MAIT cell subtypes in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • ABIRISK Consortium
Vis graf over relationer

A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally followed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a. We propose that BCR analysis of phenotypically selected cell subsets or tissues might be more informative.

OriginalsprogEngelsk
Artikelnummer577932
TidsskriftJournal of Neuroimmunology
Vol/bind370
Sider (fra-til)577932
ISSN0165-5728
DOI
StatusE-pub ahead of print - 14 jul. 2022

Bibliografisk note

Copyright © 2022. Published by Elsevier B.V.

ID: 79689646